Over the past few weeks,
communicable disease surveillance teams and public health professionals have been on alert due to the increasing number of isolated measles cases in Central Canada.
As of today, 4 cases of measles in Alberta and 10 cases in Saskatchewan been
have been confirmed since the start of 2014.1,2
Now, 4 and 10 cases seem like a very small number compared
to hundreds of cases of sexually transmitted infections and influenza; why do
we make such a big deal when the cases are measles related? In order to
understand the situation, we must look at the background and epidemiology of
the disease.
Background of Measles
Measles is a highly contagious infectious
disease caused by the virus Morbillivirus
of the Paramyxoviridae family. The
culprit is a spherical, non-segmented, negative sense RNA virus that zoonotic
in origin.3 It is believed that cross-species transmission of the
virus may have occurred approximately 10, 000 years ago. The first documented case of measles dates
back to ~900CE, where Muhammad ibn Zakariya ar-Razi, a Persian philosopher and
physician, published a book that attempted to distinguish measles from
smallpox.4 In 1757, a Scottish physician named Francis Home
discovered that measles arose from an infectious agent by transmitting measles
to healthy individuals. He inoculated the blood of infected patients to the
skin of health people and transferred the virus to 10 out of 12 health
individuals. Finally, in 1954, the virus was isolated by Dr. Thomas Peebles In
Boston, USA.5
The virus is transmitted by contact with aerosolized
droplets from infected individuals. Once infected by the virus, the incubation
is around 10 days. Infection is
initiated when the virus enters the cells of the respiratory tract, oropharynx
or conjunctivae.3 Two to four days following infection, the virus
proliferates in the respiratory mucosa and spreads through the lymphatic system.
The virus then enters the bloodstream and affects major target organs. It is at
this point, around 7-10 days post infection, when symptoms such as cough, runny
nose, sore throat, red eyes, fever, malaise and light sensitivity begin to
appear.6 These initial symptoms progressively worsen for the next
fours days and small white spots, known as Koplik’s spots, become visible
inside the mouth and throat. About 2 weeks after the infection, characteristic
rash of measles will appear starting from behind the ears, neck, hairline
towards the face, trunk, arms and finally the legs and feet.3 The
rash arises as a result of the immune response to the replicating virus and
fades slowly in the progressive order. Measles infection can result in
complications such as bronchitis (inflammation
of the lungs), pneumonia (bacterial
infection of the lung), ear infection and encephalitis (acute inflammation of the brain).3
There is no specific treatment for measles. Treatment
often involves Tylenol, bed rest, humidified air and vitamin A supplements in
some children.6 Most people recover and develop long-term immunity
against the virus. 3However, those that do die of measles are often
vulnerable people such as children and immunocompromised individuals. In
developed countries, less than 1 in 1000 children die of measles, however in
endemic areas of developing regions the case-fatality rate is an astounding
5-10%.3
Epidemiology and
Public Health
Measles is one of the most highly contagious infectious
diseases and can only be maintained if a continuous supply of susceptible
persons exists.3 Measles is most prevalent in endemic regions and
outbreaks typically occur in the late winter and early spring due to greater
congregation of people.3 Rate of contact with infected people,
amount of protective maternal antibody and vaccination status are the factors
that determine the average age at which measles contraction occurs. In
urbanized and densely populated regions with low vaccination coverage, infants
and children and most susceptible to the disease. As the population density
decrease and vaccination coverage rates increase, the age group most burdened
by measles continues to increase.3
According
to the World Health Organization, measles is still the leading cause of death
amongst vaccine-preventable diseases in children.7 In 2010, measles
related mortality have been reduced from 535, 300 to 139, 000, a matter of 74%
in 10 years.3 In the WHO region of Americas, endemic measles haves
been completely eradicated as of 2002 and there has been no indigenous case of
measles in Canada since 1997.8 Imported cases of measles still occur
and therefore, public health professionals are conscientious of the current
measles outbreak in the Philippines that is slowly emanating into Canada.9
Measles is vaccine-preventable. The first live
attenuated vaccine was licensed in the United States in 1963 and a more
attenuated version was developed in 1968.5 The measles virus is antigenically
monotypic, meaning that the surface proteins that induce the host’s immune
system have retained its structure through time.3 This is great news
for public health because this feature indicates that vaccines developed in the
past still remains protective worldwide. In Canada, measles vaccine (MMR) is
combined with other attenuated virus such as mumps and rubella and the first
dose of vaccination is recommended at 12 months of age, once newborns lost
their passively acquired maternal antibody against the virus.10 Two
doses of vaccine are recommended to ensure complete protection.
Unfortunately, vaccine coverage has been
decreasing due to a paper published by Wakefield et al. in 1998 that claimed a relationship between
MMR vaccine and autism.5 In 2004, it was found that a lawyer with a
conflict of interest against vaccine manufacturers had recruited some of the
study subjects. Nonetheless, some people still remain convinced and vaccine
rates have decreased; resulting in an increased incidence of measles.5
What can we do?
The best way to reduce measles prevalence is to increase
vaccine coverage. Increased compliance to vaccination is necessary and proper
containment of existing measles cases is required. Currently, new methods of
vaccination, such as aerosolized administration, are being developed to increase
rate of vaccination.11 Furthermore, organizations such the WHO,
Center for Disease Control, Public Health Agency of Canada, and the National
Advisory Committee on Immunization, are releasing statistical data and
information to educate the public on the effectiveness and safeness of MMR and
reduce the stigma around the vaccines.7-8,12-14 Lastly, some
organization such as the Alberta Health and Wellness has developed a 10-year
strategy to increase immunization coverage. Some point in this strategy
include, providing publicly funded immunization programs, reviewing adult
immunization status, providing booster vaccination and targeting vaccination to
the vulnerable population.15